Inborn differences within Leishmania species, the pertinent disease and a good understanding of the immunopathological mechanisms displayed by CD4+ and CD8+ T cells must be kept in mind when planning new therapeutic and vaccine strategies in human leishmaniasis. This evidence concerns the gene CD8A and leishmaniasis.